JP2014532758A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532758A5
JP2014532758A5 JP2014541011A JP2014541011A JP2014532758A5 JP 2014532758 A5 JP2014532758 A5 JP 2014532758A5 JP 2014541011 A JP2014541011 A JP 2014541011A JP 2014541011 A JP2014541011 A JP 2014541011A JP 2014532758 A5 JP2014532758 A5 JP 2014532758A5
Authority
JP
Japan
Prior art keywords
day
drug
dose
uric acid
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014541011A
Other languages
English (en)
Japanese (ja)
Other versions
JP6202633B2 (ja
JP2014532758A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/059394 external-priority patent/WO2013066349A1/en
Publication of JP2014532758A publication Critical patent/JP2014532758A/ja
Publication of JP2014532758A5 publication Critical patent/JP2014532758A5/ja
Application granted granted Critical
Publication of JP6202633B2 publication Critical patent/JP6202633B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014541011A 2011-11-04 2011-11-04 ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法 Expired - Fee Related JP6202633B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059394 WO2013066349A1 (en) 2011-11-04 2011-11-04 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016206043A Division JP6368756B2 (ja) 2016-10-20 2016-10-20 ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法

Publications (3)

Publication Number Publication Date
JP2014532758A JP2014532758A (ja) 2014-12-08
JP2014532758A5 true JP2014532758A5 (enExample) 2015-01-22
JP6202633B2 JP6202633B2 (ja) 2017-09-27

Family

ID=48192533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014541011A Expired - Fee Related JP6202633B2 (ja) 2011-11-04 2011-11-04 ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法

Country Status (13)

Country Link
EP (1) EP2773336A4 (enExample)
JP (1) JP6202633B2 (enExample)
KR (1) KR20140121383A (enExample)
CN (2) CN104066427A (enExample)
AU (1) AU2011380507B2 (enExample)
CA (1) CA2859686C (enExample)
CL (1) CL2014001155A1 (enExample)
IL (1) IL232386A0 (enExample)
MX (1) MX357507B (enExample)
NZ (1) NZ624708A (enExample)
SG (1) SG11201402032RA (enExample)
WO (1) WO2013066349A1 (enExample)
ZA (1) ZA201403575B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013245675B2 (en) * 2012-04-13 2017-02-09 Cymabay Therapeutics, Inc. Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
JP6368756B2 (ja) * 2016-10-20 2018-08-01 サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. ハロフェナートまたはハロフェン酸および第2の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
CN108014108A (zh) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用
JP7086980B2 (ja) * 2017-10-26 2022-06-20 大塚製薬株式会社 イノシトールリン酸含有組成物
WO2021186250A2 (en) * 2020-03-15 2021-09-23 Allen Davidoff Methods of treating viral infections and health consequences

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
WO2011032175A1 (en) * 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
US9023856B2 (en) * 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent

Similar Documents

Publication Publication Date Title
JP2012184234A5 (enExample)
JP2014532758A5 (enExample)
JP2013528655A5 (enExample)
JP2014012726A5 (enExample)
JP2011515349A5 (enExample)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2012502885A5 (enExample)
JP2016512817A5 (enExample)
JP2014503593A5 (enExample)
JP2014532760A5 (enExample)
JP2016516074A5 (enExample)
JP2014507476A5 (enExample)
JP2011162558A5 (enExample)
PH12018500261B1 (en) Azole benzene derivative
JO3089B1 (ar) مشتقات ايميدازول كمثبطات لانزيمات pde10a
JP2014505107A5 (enExample)
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
EA201990664A1 (ru) Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма
JP2013087119A5 (enExample)
MX2012009600A (es) Metodo para estabilizar daño de articulacion en sujetos utilizando inhibidores de xantina oxidoreductasa.
NZ624708A (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
JP2011068692A5 (enExample)
PH12014502282A1 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
JP2013507382A5 (enExample)
JP2014532759A5 (enExample)